Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Back on target

Nature Biotechnology volume 31, pages 191–193 (2013)Cite this article

Subjects

Recent clinical success of antibody-drug conjugates is resparking interest in the technology for tackling unmet cancer needs. Sarah Webb investigates.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Chattanooga, Tennessee

    Sarah Webb

Authors
  1. Sarah Webb
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Webb, S. Back on target. Nat Biotechnol 31, 191–193 (2013). https://doi.org/10.1038/nbt.2520

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2520

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research